RESEARCH MAP ─ 印
Government Arts College
｜論文数 13 件
国
印
type
大学
論文数
13 件
name_en
Government Arts College
RESEARCHERS
当機関を主所属とする 3 本以上の研究者は、当媒体の名寄せ結果では現時点で登録されていません。
論文一覧（発表年 降順）
索引済み 0 件 / 索引付与待ち 13 件 ・abstract（要約）は表示しませんPENDING INDEX ─ 索引付与待ち（最新論文・13 件）
PubMed 側で MeSH 索引が付与されると、自動で上のセクションに移動します。最新の ahead-of-print 論文は索引付与に数ヶ月かかります。
2026
2026.03.27
Crystal structure and Hirshfeld surface analysis of ethyl 2-amino-4-(4-chloro-phen-yl)-5,6,7,8,9,10-hexa-hydro-cyclo-octa-[
Pazhamalai S, Jayakodi C, Mahalakshmi V, Selvan R, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2026
2026.01.08
Crystal structure and Hirshfeld surface analysis of 1-(2-chloro-acet-yl)-3-methyl-2,6-bis-(4-methylphen-yl)piperidin-4-one.
Divyabharathi S, Rajeswari K, Vidhyasagar T, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2026
2026.01.01
Crystal structure and Hirshfeld surface analysis of 2-oxo-4-phenyl-2,5,6,7,8,9-hexa-hydro-1
Rajapandiyan U, Rajkumar M, Manikandan H, Rajathi V, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.10.09
Crystal structure and Hirshfeld surface analysis of 1,3,3-trimethyl-2,6-di-phenyl-piperidin-4-yl 2-phenyl-prop-2-enoate.
Ananthabharathi A, Janarthanan S, Gopalakrishnan M, Pazhamalai S, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.09.05
Crystal structure and Hirshfeld surface analysis of
Janarthanan S, Meenambigai G, Mahalakshmi V, Kavitha M, Selvan R, Pazhamalai S, ほか 1 名
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.07.23
Crystal structure and Hirshfeld surface analysis of 3-[(E)-2-(2-bromo-4,5-di-meth-oxy-phen-yl)ethen-yl]-5,5-di-methyl-cyclo-hex-2-en-1-one.
Rajkumar M, Rajapandiyan U, Manikandan H, Rajathi V, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.06.12
Crystal structures and Hirshfeld surface analyses of di-phenyl-methyl 2-(3,5-di-meth-oxy-phen-yl)acetate and di-phenyl-methyl 2-(3,4,5-tri-meth-oxy-phen-yl)acetate.
Kavitha M, Jayakodi C, Meenambigai G, Janarthanan S, Pazhamalai S, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.05.09
Crystal structure and Hirshfeld surface analysis of (E)-2-cyano-N'-(3,4,5-tri-meth-oxy-benzyl-idene)acetohydrazide.
Maheswari S, Senthilkumar S, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2025
2025.04.08
Crystal structure, Hirshfeld surface analysis and DFT studies of 4-amino-
Maheswari S, Senthilkumar S, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2024
2024.09.12
Crystal structure, Hirshfeld surface analysis, DFT optimized mol-ecular structure and the mol-ecular docking studies of 1-[2-(cyano-sulfan-yl)acet-yl]-3-methyl-2,6-bis-(4-methyl-phen-yl)piperidin-4-one.
Karthiga A, Divyabharathi S, Shalo R, Rajeswari K, Vidhyasagar T, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2023
2023.03.28
Crystal structures of (12E)-12-(4-benzyl-idene)-7,7,16-trimethyl-3-(4-methyl-phen-yl)-1-oxa-16-aza-tetra-cyclo-[11.2.1.02,11.04,9]hexa-deca-2(11),4(9)-dien-5-one and (12E)-12-(4-bromo-benzyl-idene)-73-(4-bromo-phen-yl)-,7,16-trimethyl-10-oxa-16-aza-tetra-cyclo-[11.2.1.02,11.04,9]hexa-deca-2(11),4(9)-dien-5-one.
Meenatchi C, Vishnupriya R, Suresh J, Rubina S, Selvanayagam S, Bhandari S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
2017
2017.11.17
Crystal structures of salen-type ligands 2-[(1E)-({1-(3-chloro-phen-yl)-2-[(E)-(2-hy-droxy-benzyl-idene)amino]-prop-yl}imino)-meth-yl]phenol and 2-[(1E)-({1-(4-chloro-phen-yl)-2-[(E)-(2-hy-droxy-benzyl-idene)amino]-prop-yl}imino)-meth-yl]phenol.
Gayathri A, Rajeswari K, Vidhyasagar T, Selvanayagam S
Acta crystallographica. Section E, Crystallographic communications
PubMed →
※ 論文の本文・abstract（要約）は PubMed（出典）をご参照ください。当機関の論文一覧は、著者所属の名寄せ結果に基づきます。同名別人・改称・移籍などの可能性があり、随時メンテナンスします。商品・効能との対応関係は提示しません（§2.4）。